SPECT scan targeting GPC3 for liver cancer
Part of Cancer clinical trials.
This trial uses a special SPECT scan that targets GPC3, a protein found on some liver cancer cells, to see if it can help detect or monitor hepatocellular carcinoma (HCC). It may be an option for people suspected of having HCC, diagnosed with it, or experiencing a recurrence after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal representative must sign a consent form agreeing to the study
- You must be willing to follow all study procedures and attend all visits
- You have a strong suspicion of liver cancer or a confirmed diagnosis of hepatocellular carcinoma (HCC) and are generally in good health
- You have had liver cancer that came back after previous treatment
- If you are a woman who could become pregnant, you must use birth control for at least 1 month before screening and throughout the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new PET imaging method that targets GPC3, a protein often found in liver cancer cells. It may help doctors see and understand liver cancer better, especially in people with newly diagnosed or recurrent disease.
This trial uses a special PET scan that targets a protein found in liver cancer cells. It aims to see if this new scan works better than an enhanced MRI to find liver cancer. If you have suspected or confirmed liver cancer, this study might help guide your care.
This study uses a special PET/CT scan that targets a protein (GPC3) found in liver cancer cells. The goal is to see how well it can detect or track liver cancer, whether it's newly diagnosed or has been treated before.
This study tests a new type of imaging scan (called 68Ga-NYM207 PET/CT) that may help doctors better find and understand liver cancer. You would receive the scan once to see if it helps doctors plan your treatment or monitor your cancer.
This trial studies whether a special fluorescent dye that targets GPC3 can help surgeons find liver cancer more clearly during an operation. It may improve how accurately tumor tissue is identified while you have surgery for hepatocellular carcinoma.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.